STOCK TITAN

Predictive Oncology Inc - POAI STOCK NEWS

Welcome to our dedicated news page for Predictive Oncology (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Predictive Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Predictive Oncology's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.65%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.09%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.7%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
Predictive Oncology Inc

Nasdaq:POAI

POAI Rankings

POAI Stock Data

7.15M
3.62M
3.14%
9.1%
0.63%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Eagan

About POAI

predictive oncology (nasdaq: poai) is focused on the use of data and artificial intelligence (ai) to develop personalized cancer therapies, which can lead to more effective treatments and improved patient outcome. the company has several tools that support its mission of bringing precision medicine to the diagnosis of cancer. through its subsidiaries, predictive oncology’s portfolio of assets includes the following: - a database of clinically validated historical and outcome data from patient tumors - an in-house clinical laboratory improvement amendments (clia)-certified lab - a “smart” patient-derived tumor profiling platform - an in-house bioinformatics artificial intelligence (ai) platform - a new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options - an fda-approved fluid collection and disposal system using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries